Pembrolizumab

ATC L01FF02

articles: 2
regulatory signals: 0
cases: 0

Articles on pembrolizumab

Review 05.11.2026

Pembrolizumab in laryngeal and pharyngeal tumors: partial and complete regression in two clinical cases

Consider the potential role of immunotherapy in multidisciplinary treatment planning for laryngeal and pharyngeal tumors. The authors emphasize assessing PD-L1 expression using CPS for patient selection.

#nivolumab #pembrolizumab clinicaloncology.com.ua

Review 05.11.2026

Ivonescimab plus chemotherapy: overall survival advantage in advanced NSCLC

New combinations may influence first-line standards for advanced NSCLC without oncogenic drivers. Confirmation in broader populations remains the aim of ongoing phase III trials.

#sacituzumab tirumotecan #pembrolizumab #ivonescimab d8miq7k9f04rm.cloudfront.net

Interactions mentioned in the articles

Ivonescimab
Nivolumab
Sacituzumab tirumotecan

Digest for physicians

Subscribe to be among the first to get the digest when we launch it.

Similar substances

Nivolumab 2 articles
Rituximab 2 articles
Daratumumab 1 article